Sanofi led a $75 million Series B in Altesa, a rhinovirus antiviral biotech run by a former FDA acting commissioner, to support mid-stage clinical development.
Longevity News
Sanofi has backed the $75 million series B of a rhinovirus-focused biotech helmed by a former FDA acting commissioner.
Source: FierceBiotech - All • Published: 19 Feb 2026, 15:24
Continue exploring
Related longevity signals
Longevity TechnologyLongevica appoints ex-Genentech biotech veteran as CEOLongevica names a new CEO as it pivots toward preclinical drug development; read an update on leadership and strategic direction.PR NewswirePixelgen Technologies Closes $15.5M Oversubscribed Series B to Accelerate Global ExpansionPixelgen's funding and board moves are the focus, previewing an article about a life‑science startup accelerating commercialization and global growth.Lifespan.ioA Million-Person Study Finds a Protective Metabolic GeneHuman genetics research exploring metabolic regulation and disease risk, previewing an article that examines gene-based discoveries and potential therapeutic pathways.Fight Aging!Bacterial Lipoic Acid Protein Ligase A Improves Mammalian Mitochondrial Function and HealthThis article previews research on using a bacterial enzyme to boost mitochondrial protein modification and overall cellular energy, framed as a potential metabolic-enhancing therapy. It invites readers curious about cross-species gene therapy approaches aimed at improving healthspan and age-related function.